JOURNAL HOME CME HOME THIS MONTH PAST ISSUES ETOC COLLECTIONS AUTHORS REVIEWERS EDITORIAL BOARD FEEDBACK RSS HELP
		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Beath, S. M. Articles by Oyen, L. J. Search for Related Content PubMed PubMed Citation Articles by Beath, S. M. Articles by Oyen, L. J.

---

CARDIOVASCULAR ANESTHESIA

Plasma Aprotinin Concentrations During Cardiac Surgery: Full- Versus Half-Dose Regimens

Susan M. Beath, MD^*, Gregory A. Nuttall, MD, David N. Fass, PhD, William C. Oliver, Jr., MD, Mark H. Ereth, MD, and Lance J. Oyen, Pharm D BCPS^§

Departments of *Cardiovascular Anesthesiology and Anesthesiology, Mayo Graduate School of Medicine; and Departments of Biochemistry and Molecular Biology, and §Hospital Pharmacy, Mayo Clinic, Rochester, Minnesota

Address correspondence and reprints requests to Gregory A. Nuttall, MD, Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905. Address e-mail to nuttall.gregory{at}mayo.edu

Aprotinin is an effective but expensive drug used during cardiac surgery to reduce blood loss and transfusion requirements. Currently, aprotinin is administered to adults according to a fixed protocol regardless of the patient’s weight. The purpose of this study was to determine aprotinin levels in patients receiving full- and half-dose aprotinin regimens by a simple functional aprotinin assay and to design a more individualized aprotinin dosage regimen for cardiac surgical patients. The mean plasma aprotinin concentration peaked 5 min after the initiation of cardiopulmonary bypass (full 401 ± 92 KIU/mL, half 226 ± 56 KIU/mL). The mean plasma aprotinin concentration after 60 min on cardiopulmonary bypass was less (full 236 ± 81 KIU/mL, half 160 ± 63 KIU/mL). There was large variation in the aprotinin concentration among patients. A statistically significant correlation was found between aprotinin concentration and patient weight (r² = 0.67, P < 0.05).

Implications: The current dosing schedule for aprotinin results in a large variation in aprotinin plasma concentrations among patients and a large variation within each patient over time. We combined the information provided by our study with that of a previous pharmacokinetic study to develop a potentially improved, weight-based, dosing regime for aprotinin.

This article has been cited by other articles:

				S. A. Olenchock Jr, P. H.U. Lee, T. Yehoshua, S. A. Murphy, J. Symes, and G. Tolis Jr Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients. Ann. Thorac. Surg., August 1, 2008; 86(2): 560 - 566. [Abstract] [Full Text] [PDF]

				M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF]

				M. T. Ganter, A. Monn, R. Tavakoli, M. Genoni, R. Klaghofer, L. Furrer, H. Honegger, and C. K. Hofer Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot. Eur. J. Cardiothorac. Surg., August 1, 2006; 30(2): 278 - 284. [Abstract] [Full Text] [PDF]

				J. A. Howard Commercialization of Biopharmaceutical and Bioindustrial Proteins from Plants Crop Sci., January 31, 2005; 45(2): 468 - 472. [Abstract] [Full Text] [PDF]

				D. R. McIlroy and A. J. Silvers Recombinant Factor VIIa for Life-Threatening Bleeding in High-Risk Cardiac Surgery Despite Full-Dose Aprotinin Anesth. Analg., July 1, 2004; 99(1): 27 - 30. [Abstract] [Full Text] [PDF]

				W. C. Oliver Jr, D. N. Fass, G. A. Nuttall, J. A. Dearani, L. M. Schrader, D. R. Schroeder, M. H. Ereth, and F. J. Puga Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1670 - 1677. [Abstract] [Full Text] [PDF]

				A. Koster, S. Huebler, F. Merkle, T. Hentschel, M. Grundel, T. Krabatsch, L. Tambeur, M. Praus, H. Habazettl, W. M. Kuebler, et al. Heparin-Level-Based Anticoagulation Management During Cardiopulmonary Bypass: A Pilot Investigation on the Effects of a Half-Dose Aprotinin Protocol on Postoperative Blood Loss and Hemostatic Activation and Inflammatory Response Anesth. Analg., February 1, 2004; 98(2): 285 - 290. [Abstract] [Full Text] [PDF]

				C. Schmidt, A. Reich, H. Van Aken, D. Stanojevic, M. Booke, G. A. Nuttall, and L. J. Oyen Dosing Aprotinin: Is Weight-Adjustment the Way to Go? * Response Anesth. Analg., December 1, 2002; 95(6): 1820 - 1821. [Full Text] [PDF]

				G. A. Nuttall, D. N. Fass, L. J. Oyen, W. C. Oliver Jr., and M. H. Ereth A Study of a Weight-Adjusted Aprotinin Dosing Schedule During Cardiac Surgery Anesth. Analg., February 1, 2002; 94(2): 283 - 289. [Abstract] [Full Text] [PDF]

				D. Royston, R. Cardigan, C. Gippner-Steppert, and M. Jochum Is Perioperative Plasma Aprotinin Concentration More Predictable and Constant After a Weight-Related Dose Regimen? Anesth. Analg., April 1, 2001; 92(4): 830 - 836. [Abstract] [Full Text] [PDF]

Anesthesia & Analgesia® is published for the International Anesthesia Research Society® by Lippincott Williams & Wilkins with the assistance of Stanford University Libraries' HighWire Press®. Copyright 2006 by the International Anesthesia Research Society. Online ISSN: 1526-7598   Print ISSN: 0003-2999